Currax Pharmaceuticals is a specialty biopharmaceutical company dedicated to expanding patient access to clinically differentiated prescription medicines worldwide. Currax is primarily focused on the number one and number two causes of preventable death in the U.S., obesity and smoking. Obesity and smoking together result in severe co-morbidities, deaths, and significant expense to our healthcare system unparalleled to any other disease states. Currax is committed to transforming the treatment of these diseases. Currax has over 20 products in its portfolio including: CONTRAVE®, the number one prescribed branded oral weight-loss medication in the US, ONZETRA® Xsail®, Silenor®, Treximet®. The Company has more than 150 employees and is headquartered in Brentwood, TN.
